Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1948

1.

Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.

Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML.

Medicine (Baltimore). 2017 Jun;96(22):e6984. doi: 10.1097/MD.0000000000006984.

2.

Differences in IP‑10, TLR4 and IRF5/3 between SVR and non‑SVR HCV‑1 patients treated with PEG‑IFN and ribavirin.

Zhang M, Jiang Y, Xiao X, Peng M, Peng F, Gong G.

Mol Med Rep. 2017 Apr;15(4):2318-2324. doi: 10.3892/mmr.2017.6229. Epub 2017 Feb 22.

PMID:
28259968
3.

A Neonatal Murine Model of Coxsackievirus A6 Infection for Evaluation of Antiviral and Vaccine Efficacy.

Zhang Z, Dong Z, Wei Q, Carr MJ, Li J, Ding S, Tong Y, Li D, Shi W.

J Virol. 2017 Apr 13;91(9). pii: e02450-16. doi: 10.1128/JVI.02450-16. Print 2017 May 1.

PMID:
28250116
4.

A real-world impact of cost-effectiveness of pegylated interferon/ribavarin regimens on treatment-naïve chronic hepatitis C patients in Taiwan.

Tsai PC, Liu TW, Hsieh MH, Yeh ML, Liang PC, Lin YH, Huang CI, Huang CF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML.

Kaohsiung J Med Sci. 2017 Jan;33(1):44-49. doi: 10.1016/j.kjms.2016.10.008. Epub 2016 Nov 18.

5.

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.

Hlaing NK, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR.

World J Gastroenterol. 2016 Nov 21;22(43):9613-9622.

6.

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.

Zhang Y, Cao Y, Zhang R, Zhang X, Lu H, Wu C, Huo N, Xu X.

PLoS One. 2016 Nov 3;11(11):e0165658. doi: 10.1371/journal.pone.0165658. eCollection 2016.

7.

Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.

Salama H, Medhat E, Shaheen M, Zekri AN, Darwish T, Ghoneum M.

Int J Immunopathol Pharmacol. 2016 Dec;29(4):647-653. Epub 2016 Oct 31.

PMID:
27799299
8.

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.

Kumada H, Mochida S, Suzuki F, Chayama K, Karino Y, Nakamura K, Fujimoto G, Howe AY, Ludmerer SW, Mobashery N.

J Gastroenterol Hepatol. 2016 Oct;31(10):1674-1683. doi: 10.1111/jgh.13328.

PMID:
26936417
9.

Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.

Nordstrom EM, Keniston A, Baouchi F, Martinez-Camacho A.

Eur J Gastroenterol Hepatol. 2017 Jan;29(1):10-16.

PMID:
27755117
10.

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.

Flisiak R, Shiffman M, Arenas J, Cheinquer H, Nikitin I, Dong Y, Rana K, Srinivasan S.

PLoS One. 2016 Oct 17;11(10):e0164563. doi: 10.1371/journal.pone.0164563. eCollection 2016.

11.

Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.

Beck KR, Kim N, Khalili M.

Dig Dis Sci. 2016 Dec;61(12):3602-3608. Epub 2016 Oct 14.

PMID:
27743164
12.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

Rodriguez-Torres M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M.

Ann Hepatol. 2016 Nov-Dec 2016;15(6):834-845.

13.

Impact of hepatitis C virus core mutations on the response to interferon-based treatment in chronic hepatitis C.

Sultana C, Oprişan G, Teleman MD, Dinu S; HepGen 88/2012 Project Team, Oprea C, Voiculescu M, Ruta S.

World J Gastroenterol. 2016 Oct 7;22(37):8406-8413.

14.

FREQUENCY OF THE MDR1 GENE POLYMORPHISM RS1045642 (C3435T) IN HCV-HIV CO-INFECTED PATIENTS.

Marasca GS, Machado AL, Kretzmann NA Filho, Souza AC, Mattos AA, Kliemann D, Tovo CV, Veiga AB.

Arq Gastroenterol. 2016 Oct-Dec;53(4):246-249. doi: 10.1590/S0004-28032016000400007.

15.

Occurrence of hepatocellular carcinoma 13 years after successful antiviral treatment for HCV infection.

Puoti C, Lanzetta G, Scotti E.

J Gastrointestin Liver Dis. 2016 Sep;25(3):408-9. doi: 10.15403/jgld.2014.1121.253.hcv. No abstract available.

16.

Body Composition Changes in Patients with Chronic Hepatitis C.

Barbu EC, Chiţu-Tișu CE, Lazăr M, Olariu CM, Olteanu D, Bojincă M, Abagiu AO, Aramă V, Ion DA, Bădărău IA.

J Gastrointestin Liver Dis. 2016 Sep;25(3):323-9. doi: 10.15403/jgld.2014.1121.253.hpc.

17.

Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.

El-Karaksy HM, Sharaf SA, Mandour IA, Mogahed EA, Rady NH, El-Mougy FA.

Hum Immunol. 2016 Dec;77(12):1248-1253. doi: 10.1016/j.humimm.2016.09.005. Epub 2016 Sep 19.

PMID:
27660094
18.

Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment.

Indolfi G, Nebbia G, Cananzi M, Maccabruni A, Zaramella M, D'Antiga L, Grisotto L, Azzari C, Resti M; and the Italian Study Group for Treatment of Chronic Hepatitis C in Children.

Pediatr Infect Dis J. 2016 Dec;35(12):1300-1303.

PMID:
27636721
19.

Hepatitis C virus: Promising discoveries and new treatments.

Bastos JC, Padilla MA, Caserta LC, Miotto N, Vigani AG, Arns CW.

World J Gastroenterol. 2016 Jul 28;22(28):6393-401. doi: 10.3748/wjg.v22.i28.6393. Review.

20.

Association between IL28B rs12979860 single nucleotide polymorphism and the frequency of colonic Treg in chronically HCV-infected patients.

Mehta M, Hetta HF, Abdel-Hameed EA, Rouster SD, Hossain M, Mekky MA, Khalil NK, Mohamed WA, El-Feky MA, Ahmed SH, Daef EA, El-Mokhtar MA, Abdelwahab SF, Medhat A, Sherman KE, Shata MT.

Arch Virol. 2016 Nov;161(11):3161-9. doi: 10.1007/s00705-016-3015-4. Epub 2016 Aug 20.

PMID:
27544760

Supplemental Content

Loading ...
Support Center